Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
M2Bio Sciences Inc, formerly Wuhan General Group (China) Inc is an alternative medicinal and botanicals company focused on the application of emerging technologies as well as the clinical research and health application of cannabidiol (CBD)-based medicine to the human and pet care industry for cancer, cardiovascular, mental disorders, chronic pain, and others in Canada, the United States, Europe, and Australia. It supplies medical grade CBD products, and superior patient care.
Montreal, QC, H9R 0A5